Everolimus Does Not Overcome Trastuzumab ResistanceEverolimus Does Not Overcome Trastuzumab Resistance
Inhibiting the PI3K/mTOR pathway did not improve progression-free survival when added to chemotherapy and trastuzumab in women with advanced breast cancer. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Herceptin | Women